To the Editor: Aprill and colleagues (1) report valuable data on small adrenal nodules in patients with von Hippel-Lindau disease. Their patients show the difficulties of a preoperative diagnosis of pheochromocytoma when the adrenal lesions are so small. However, the use of adrenal vein sampling and a catecholamine assay might have helped. The St. Bartholomew's Hospital experience in four unrelated patients with von Hippel-Lindau disease shows its value (2) . In this series, adrenal vein noradrenaline-to-adrenaline ratios were measured in patients with small adrenal masses that had been found on CT scans. Radiolabeled metaiodo-benzylguanidine (MIBG) and T2-weighted magnetic resonance imaging (MRI) had not been helpful in determining whether these masses were pheochromocytomas. Every adrenal gland with histologically confirmed pheochromocytoma had an adrenal vein adrenaline-to-noradrenaline ratio greater than 1. Adrenal glands with nonpheochromocytoma lesions (eight patients with the Conn syndrome were used as controls) had adrenal vein noradrenaline-to-adrenaline ratios between 0.06 and 0.6.
Venous sampling may have been valuable in the first and fourth patients described by Aprill and colleagues but less helpful in patients 2 and 3, who had other findings suggesting pheochromocytoma (positive MIBG scintigraphy or a high T2-weighted signal on MRI). Although well-documented (2-4), the hazards of venous sampling are minimal in experienced hands, and its benefits exceed the risks.
In response: We concur with Dr. Siddiqui's comments that CT scanning is highly sensitive in visualizing intra-adrenal pheochromocytomas (1) . However, CT scanning alone is not sufficient because of its relatively low specificity in distinguishing pheochromocytomas from other adrenal masses such as adrenal incidentalomas (1, 2) . Although MIBG scanning and MRI with T2-weighted images may be more specific for pheochromocytoma (1) , diagnosis rests mainly on a high clinical suspicion (particularly in familial syndromes such as von Hippel-Lindau disease) and appropriate biochemical testing.
The disparity in the surgical specimen and CT scan sizes of the left adrenal mass in patient 1 was caused by several factors. A re-evaluation of the original CT scan showed the nodule to be closer to 1.5 cm in greatest diameter. The fixed and sectioned adrenal mass was 1 cm in total diameter, in contrast to 2 cm as noted in the operative report. It was composed of an irregular, nonencapsulated 0.5-cm internal pheochromocytoma component surrounded by a rim of normal adrenal cortical tissue. The slight difference in the total diameter of the mass as measured by CT scanning compared with histologic measurement was probably due to fixation artifact and shrinkage. Although we agree that the "typical" 3-to 5-cm pheochromocytoma is generally encapsulated (3), our experience and that of others show that small, clinically silent lesions may not be encapsulated (Ogorzalek JM. Personal communication).
The CT scan of the abdomen in patient 2 showed a 3.5-cm left adrenal nodule and a normal right adrenal gland. Bilateral adrenalectomy (done after bilateral positive uptake on MIBG scan-ning) showed a 4.0-cm left adrenal mass and a 2.2-cm right adrenal mass that were both encapsulated and salmon-colored, with adherent rims of residual yellow adrenal cortical tissue. Both masses were histologically confirmed to be pheochromocytomas. Of interest, the CT scan did not show the right adrenal mass. None of our patients have shown any evidence of malignancy.
We agree with Jain and colleagues' suggestion that venous sampling and determination of the adrenal vein noradrenalineto-adrenaline ratio are valuable (4) for confirming an intra-adrenal pheochromocytoma. However, three of the four patients described by Chew and colleagues (4) had clearly elevated urinary noradrenaline excretion, and venous sampling showed a contralateral second tumor in each. Thus, venous sampling is effective in locating small bilateral pheochromocytomas in patients with elevated 24-hour urinary norepinephrine levels. Our patient 1 had normal urinary and plasma catecholamine values, so we do not know if venous sampling would have shown an intradrenal pheochromocytoma. Even in patient 3, venous sampling may not have disclosed a pheochromocytoma at the initial evaluation when the patient was normotensive and had normal biochemical test results. Further studies of adrenal venous sampling are necessary to answer this question.
Management of Atrial Fibrillation
To the Editor: Important miscalculations were made in a recently published Markov decision analysis of atrial fibrillation (1) . In their review comparing warfarin with no treatment, the authors considered randomized, placebo-controlled trials that evaluated intention to treat and all-cause mortality. This was only slightly altered regarding quinidine. When evaluating amiodarone, the authors considered open-label, nonrandomized studies and only looked at drug-associated mortality. Second, Disch and colleagues (1) may have underestimated the amtodarone-associated annual mortality rate at 0.09%. One study acknowledged that amiodarone proarrhythmia was underestimated and reported a 25% incidence of pulmonary fibrosis over 5 years, with a higher incidence in those older than 60 years of age (2) . A review of pulmonary fibrosis listed the mortality rate as 23% (3) . If the mortality rate related to pulmonary fibrosis were only 10%, the amiodarone-associated mortality rate would be at least 2% (20 times higher than 0.09%). Third, the Markov decision analysis relied on studies with short-term follow-up periods inadequate to analyze quality of life. Side effects of amiodarone often depend on the dose duration. We reported a few side effects over a 1.8-year follow-up period (4) . Over the next 5 years, however, most of our patients could not tolerate amiodarone and required dose reductions to subtherapeutic levels, resulting in a resumption of atrial fibrillation. Only Herre and colleagues (2) have published a report with a mean 5-year follow-up that evaluated long-term side effects. Herre (5) later cautioned about the sideeffect profile of amiodarone for atrial fibrillation. Disch and colleagues also failed to compare the financial cost of amiodarone with that of other therapies. Amiodarone and its necessary follow-up laboratory testing are more expensive than the alternative therapies. We agree that amiodarone should be considered for the treatment of atrial fibrillation, but only in high-risk or refractory patients. To the Editor: In their article on the management of chronic asymptomatic atrial fibrillation, Disch and colleagues (1) used a decision model to conclude that low-dose amiodarone or quinidine would be preferred over warfarin, primarily through a reduction in stroke risk (1) . They concluded this in the context of several clinical trials showing the effectiveness of warfarin in reducing stroke risk in patients with atrial fibrillation (2) but had no clinical trial data supporting the effectiveness of quinidine, amiodarone, or any other antiarrhythmic agent for this purpose.
Michael
Their conclusion appears to hinge on two subtle assumptions embedded in the structure of the model. The first is that the presence of normal sinus rhythm on periodic electrocardiograms recorded during office visits indicates that asymptomatic atrial fibrillation is not occurring. In fact, asymptomatic atrial fibrillation occurs frequently in patients who are being followed for symptomatic atrial fibrillation (3) . For the patients addressed in this analysis-those whose atrial fibrillation is asymptomatic-this phenomenon may be more common and more difficult to detect. The second assumption is that persons with atrial fibrillation who revert to normal sinus rhythm have a risk for stroke similar to that of persons who have never had atrial fibrillation. The risk for stroke is nearly as high in patients with intermittent atrial fibrillation as it is in patients with chronic atrial fibrillation (4). In addition, the risk factors common to stroke and atrial fibrillation (for example, atherosclerotic heart disease) do not disappear with successful cardioversion or with antiarrhythmic therapy. The authors acknowledge this risk and attempt to explain it by varying the underlying annual probability of stroke from a baseline of 0.1% to 1%. However, the upper bound of this range is probably too low to account for the many stroke risk factors among persons with atrial fibrillation who had successful cardioversion.
Despite the tenuous nature of the underlying assumptions, the conclusions were stated rather strongly. As clinicians concerned with the practical implications this analysis presented, we wonder whether modifying the model to account for the questions raised here would result in the disappearance of the apparent preference for antiarrhythmics. In response: Although the randomized trials of warfarin in atrial fibrillation to which Brodsky and colleagues refer did report "all-cause" mortality, we only abstracted rates of stroke, major bleeding events, and fatalities to estimate these probabilities for our decision model. For the hypothetical cohorts of patients assigned to the "warfarin" or "no treatment" strategies, the "die from other causes" arm of the model represents a baseline population-based mortality rate, not all-cause mortality from the randomized trials. Similarly, for patients taking quinidine, all-cause mortality was not used. We calculated an "excess" mortality rate by subtracting the mortality for patients in the placebo arms of the randomized trials from that of patients taking quinidine. We also reviewed each reported death to determine whether it could have been attributable to quinidine.
David Matchar, MD
As we have acknowledged, data on the use of low-dose amiodarone for atrial fibrillation are limited by the absence of randomized trials. Therefore, estimating these probabilities was somewhat more difficult. We felt the most valid method by which to estimate both toxicity and excess mortality was to pool the results of all available cohort studies using low-dose amiodarone rather than simply to choose one or two studies. In calculating their own incidence of fatal pulmonary toxicity, Brodsky and colleagues have taken the cumulative incidence of pulmonary toxicity from the study by Herre and associates (1) (in which no cases of fatal pulmonary toxicity were reported and in which many patients received high doses) and multiplied it by an arbitrarily chosen case fatality rate (10%). We feel this to be somewhat less valid. Even so, their 2% rate (or 0.4% per year over 5 years) is still lower than the threshold rate we reported (0.52%) for the warfarin strategy to have been favored over low-dose amiodarone.
The reported incidence of amiodarone-induced pulmonary toxicity varies widely but is generally lower with lower doses (2). Of note, most patients in the review referenced by Brodsky and colleagues (23% mortality rate) received more than 400 mg per day (3). In the largest case series of amiodarone-induced pulmonary toxicity of which we are aware, Dusman and colleagues (4) followed 573 patients over 10 years. No cases occurred in patients receiving less than 305 mg per day. The Cardiac Arrest in Seattle: Conventional Amiodarone Drug Evaluation (CAS-CADE) study recently found a 10% cumulative incidence of pulmonary toxicity at 3 years for patients randomly assigned to receive low-dose amiodarone, with no associated fatalities (5).
We chose not to incorporate the estimated costs of each strategy into our decision model. Although we agree with Brodsky and colleagues that these strategies should be compared on the basis of cost, this is a separate question and is beyond the scope of the present study. A formal cost-effectiveness analysis is presently under way.
Although our decision model did favor the use of low-dose amiodarone for maintenance of normal sinus rhythm over a strategy of anticoagulation with warfarin, warfarin was in fact favored over an antiarrhythmic strategy that used quinidine. Dr. Matchar and colleagues are correct, however, in stating that no randomized trials have specifically evaluated the effectiveness of any antiarrhythmic strategy for preventing strokes in patients with atrial fibrillation.
Our conclusions hinge on data derived from published studies, as well as several assumptions. The two to which Dr. Matchar
data specifically address this question. As an initial estimate of this variable, we used population-based rates from numerous population-based stroke registries. Although these rates were remarkably similar (0.09% to 0.14% per year), we felt these populations were not necessarily representative of those that develop atrial fibrillation in that the latter are more prone to have independent risk factors for stroke, including preexisting hypertension. Therefore, a wide range for sensitivity analysis was necessary. A threshold analysis (unpublished data) showed that for the warfarin strategy to be favored over low-dose amiodarone, the risk for stroke while patients received antiarrhythmic agents and experienced normal sinus rhythm would have to exceed 1.62% per year. Although not inconceivable, this would seem unlikely given the annual rate of 1.35% per year in patients who persistently experience atrial fibrillation while receiving warfarin. Perhaps future randomized trials of antiarrhythmic therapy for chronic atrial fibrillation will allow more accurate determination of this important variable.
Cryptosporidium Spread in a Group Residential Home
To the Editor: Newman and colleagues (1) describe new evidence for person-to-person transmission of Cryptosporidium parvum in urban households of northeast Brazil. They acknowledge the potentially catastrophic effects of high rates of human immunodeficiency virus (HIV) infection in endemic areas of C parvum infection. Although the endemic rate of C. parvum infection is lower in the United States, microcosms of HIV infection exist in which introduction of a single case of cryptosporidiosis could also be catastrophic. For example, an outbreak of cryptosporidiosis among HIV-infected patients in an infectious diseases ward in Denmark was traced to an ice machine contaminated by a psychotic, incontinent patient with the acquired immunodeficiency syndrome (AIDS) who had cryptosporidiosis (2). Group residential homes provide another location in which Cryptosporidium can be transmitted from one HIV-infected person to another, either by person-to-person transmission or by environmental contamination.
In the summer of 1992, we noted a cluster of cases of cryptosporidiosis among residents of two group residential homes for HIV-infected persons in the Raleigh-Durham area of North Carolina. Four cases of intestinal cryptosporidiosis occurred among the residents of the two group residential homes. The index case had previously been diagnosed with cryptosporidiosis before moving into the house. Subsequently, two of the four remaining residents of the home developed cryptosporidiosis. Possible sources of environmental transmission included a com-mon ice bucket and a common hand towel in the bathroom used by residents. During the same period, a resident of another home developed cryptosporidiosis. None of the other five residents of that home developed cryptosporidiosis. Infection control practices were more strict because of heightened awareness related to recent diagnosis of the three cases in the other home.
Group residential homes for HIV-infected patients provide a valuable service to patients who do not have family or friends willing or able to care for them. However, there is a high risk for transmission of cryptosporidiosis from one resident to another because of the high prevalence of Cryptosporidium as a cause of diarrhea among HIV-infected persons (3), the prolongation and increased severity of symptoms in persons with greater immunosuppression (4), lack of effective treatment (3), and difficulty in eradicating the organism from the environment (5). To reduce the potential for transmission of C. parvum in group residential homes, we recommend the use of strict infection control practices, including strict hand-washing after the use of the bathroom and before and after food preparation and eating, use of paper towels instead of a common cloth towel in communal areas, and use of a separate ice dispenser with a designated scoop. Environmental surfaces must be cleaned with full-strength bleach or 5% ammonia for more than 15 minutes to eradicate C. parvum.
Alison E. Heald, MD John A. Bartlett, MD Duke University Medical Center Durham, NC 27710
In response: The letter by Drs. Heald and Bartlett further suggests that C. parvum should be regarded as a highly infectious enteric pathogen. The 50% rate of secondary transmission they observed in the first group residential home is similar to the rate of potential person-to-person transmission observed in our studies in an urban slum in northeast Brazil (1) . Further evidence of the ease with which Cryptosporidia are spread comes from the apparent nosocomial aquisition of cryptosporidial infection by 45% of nurses, housestaff, and students caring for patients with AIDS and cryptosporidiosis (2) . Given the recently reported low infectious inoculum for G parvum infection in humans (3) and the hardy nature of the oocyst of this parasite, the sources of environmental transmission suggested by Heald and Bartlett seem plausible. In the future, the development of molecular diagnostic methods for C. parvum infections will enable studies to determine whether clusters of patients infected with G parvum carry the same parasite strain. These studies should also allow reservoirs of infection to be clearly identified. We concur that to limit the spread of C. parvum, strict infection control measures are necessary, particularly in crowded living conditions and for immunocompromised patients.
A Complication of Ambulatory Blood Pressure Monitoring
To the Editor: A recent review noted the rapid increase in the use of ambulatory blood pressure monitoring (1) . This procedure is considered to be well tolerated and is associated with few complications (2) . We report a case involving significant complications from such monitoring.
A 46-year-old woman was placed on 24-hour ambulatory blood pressure monitoring. Measurements were set at 20-minute intervals during the day and hourly at night. She had no history of diabetes, bleeding disorders, or easy bruisability. After 12 hours on the machine, the patient noted that she had pain in her arm and a rash on her wrist and fingers. By 24 hours, the rash had progressed and her arm was "raw and sore." The left arm had a petechial rash, erythematous streaks, and a large raw area (Figure 1) . Hematologic and clotting indices were normal, and her mean 24-hour blood pressure was 145/93 mm Hg (range, 113 to 185 mm Hg [systolic] and 68 to 125 mm Hg [diastolic]). The result of a Rumpel-Leede test for capillary fragility was negative.
We believe this to be a significant complication of ambulatory blood pressure monitoring in a patient who did not have increased capillary fragility (3), one that could lead to more serious complications (4) . The cause could be the many cuff inflations-80 attempts were required to obtain 46 successful readings. The major reasons were the inability of the pump to exceed systolic pressure (30%), movement artifacts (25%), and inadequate pulse pressure (25%). The duration of each inflation is also important. If the machine does not read correctly on the first attempt, it reinflates, maintaining pressure for up to 180 seconds. The duration of each inflation is not recorded, but, with an initial cuff failure of almost 50%, this may be significant.
It is important to be aware of this complication in ambulatory blood pressure monitoring. It may be avoided by previous patient 
Analyzing Computer-based Decision Support Systems
To the Editor: The careful analysis of computer-based decision making by Johnson and colleagues (1) is an important contribution. Although we agree with most of their conclusions, we disagree strongly with two of their criteria for methodologic adequacy.
First, they imply by their scoring system that randomization by practice or institution (rather than by patient or physician) is always preferred. Randomization in clinical trials is designed to control bias. Studies of computer-based decision support systems typically require hierarchical, clustered designs with the intervention applied to the physician (computer reminders) and the outcomes measured in patients (for example, delivery of preventive care, cost of care, and blood pressure control). Randomization by patient provides the most efficient use of data from a fixed number of patients; randomization by physician, the next most efficient; and randomization by practice, the least efficient.
Randomizing by patient or provider does increase the risk that the intervention will contaminate the control cases and reduce the chance of significant observed differences between intervention and controls; however, contamination is often weaker than expected. We have observed large effects even when physicians served as their own controls in crossover studies (2) . Furthermore, some interventions (for example, the presentation of results of complex kinetic models) are almost immune to contamination because the provider cannot carry out the intervention in the control state without the help of the computer.
Requiring that separate clinics or institutions be the unit of randomization reduces the risk for contamination but presents its own problems. If only a few clinics or practices are available, observed effects may be attributable to differences in the clinic sites, not the intervention. Obtaining many truly independent sites can be impossible (or hopelessly expensive), especially when it is necessary to integrate the intervention into institutional computer systems. Thus, the preferred unit of randomization depends on the nature of the intervention, the organization of the practice, and the hypothesis studied.
Whatever the randomization method used, the analysis must address the clustering effects within providers or institutions while allowing for the correlated outcomes of patients within each provider or practice. Several techniques (3, 4)-maximum likelihood models, quasi-likelihood models, and hierarchical Bayesian models-are now available for such analyses.
In response: McDonald and colleagues raise important points. First, the weight we gave to the unit of randomization was based on concerns about contamination. This was judged to be especially important in evaluating computerized decision support systems, particularly early in their development, and the effects to date have been small. Thus, we did not wish to bias our review against such systems by considering those that had been tested with randomization within groups to be on the same footing as those with randomization in separate, independent groups. It is true, however, that, in a given circumstance, the most appropriate approach to randomization may not be the theoretically preferable one and that our decision reduces the precision of testing for reductions in contamination.
Second, we did not require that studies assess effects on patient outcomes but accorded equal status in the scoring system to measures of clinician performance and patient outcomes. As noted in the Methods section, studies could receive full marks for measuring either, if they met the criteria stated in the Appendix. Unfortunately, we used the term "outcome" ambiguously in the scoring system, indicating the effect of the computer-based decision support system on either clinician performance or patient events. We are grateful for the opportunity to clarify this point. We do agree, however, that at least intermediate patient outcomes should be measured in the final stages of testing of computer-based decision support systems whenever feasible.
R. Brian Haynes, MD
McMaster University London, Ontario Canada L8N 375
Capitation and the Medicaid Elderly
To the Editor: Based on their study in which patients with prepaid care and patients with fee-for-service care received similar medical care, Lurie and colleagues (1) concluded that enrolling elderly Medicaid patients in prepaid health plans is not harmful. This conclusion is flawed. The primary coverage for most patients in this study was Medicare; Medicaid was only used for the copayment and deductible portion of the Medicare program and the services not covered by Medicare such as dental care, occupational therapy, and so forth. To capitate the copayment (which is already severely limited by statute) would not alter access to health care, and to imply that prepaid care is as good as feefor-service based on this maneuver is misleading.
Furthermore, in this study, capitation does not show real savings. Although the average annual Medicaid per-person expenditure was $715 lower for the prepaid group than that for the fee-for-service group, the Medicare cost for these same patients with prepaid care was $462 higher. When this increased cost is considered, it is doubtful that there are any significant savings; this is merely robbing Peter to pay Paul.
Yitzhak Twersky MD Harold Lipsky MD
Mount Sinai Services at Queens Hospital Center Jamaica, NY 11432
Medicaid covers many services that Medicare does not. We believe it is important that in this particular real-world setting, enrolling dually enrolled Medicare/Medicaid beneficiaries in managed care plans was not measurably harmful to their health.
Careful monitoring will be necessary to see if our findings are generalizable to settings in which the entire payment is capitated or to settings that serve only capitated Medicaid populations.
